Longeveron and University of Miami Expand Exclusive License Agreement, and Enter into CRADA To Facilitate Future Collaborations Agreement Provides Additional Intellectual Property and Clinical Data for Longeveron While Strengthening Research and Development Relationship
March 10, 2021 08:30 ET | Source: Longeveron Longeveron Miami, Florida, UNITED STATES
MIAMI, March 10, 2021 (GLOBE NEWSWIRE) Longeveron Inc. (NASDAQ: LGVN) ( Longeveron or Company ), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, announced today that the Company has expanded and amended its exclusive license agreement (ELA) related to Lomecel-B technology rights, and entered into a Collaborative Research and Development Agreement (CRADA) with the University of Miami (UM).
Press release content from PR Newswire. The AP news staff was not involved in its creation.
BreathDirect’s BDR-19™ Critical Care Ventilator from California’s Nectar Product Development, Receives FDA Emergency Use Authorization
March 10, 2021 GMT
LONG BEACH, Calif., March 10, 2021 /PRNewswire/ Leading medical design firm, Nectar Product Development, and its affiliated medical device company, BreathDirect™, today announced that its BDR-19™ ventilator has received Emergency Use Authorization from the U.S. Food and Drug Administration (FDA).
Approval of the BDR-19™ for the critical care of patients with ventilatory insufficiency comes after an extended review process by FDA regulators to gauge its safety and performance. The resulting design and safety features incorporate new learnings and evolved care protocols for ventilation support of COVID-19 patients and others. The BDR-19™ is now authorized for immediate medical use throughout the U.S.
Edesa Biotech Completes Enrollment for Interim Clinical Study Milestone
TORONTO, ON / ACCESSWIRE / March 9, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that it has completed enrollment of the first cohort of a Phase 2b clinical study evaluating the company s drug candidate EB01 as a monotherapy for chronic Allergic Contact Dermatitis (ACD), a potentially debilitating condition and occupational illness.
Edesa reported that all 46 subjects in the first cohort have been randomized and dosed with either Edesa s EB01 topical treatment or a placebo cream. EB01 contains a non-steroidal anti-inflammatory compound known as an sPLA2 inhibitor. Since EB01 is designed to inhibit the inflammatory process at its inception rather than after inflammation has occurred, the company believes that the drug could potentially exert a powerful anti-inflammatory effect without the safety concerns
NeuroRX and TFF Pharmaceuticals Announce Entering Into Feasibility Collaboration prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Last Updated:
COVID-19: 37-day-old Baby Becomes youngest Victim Of Pandemic In Greece
Covid-19: Becoming the youngest victim of COVID-19, a 37-day-old baby in Greece who developed ARDS after contracting the deadly coronavirus died on Monday.
Becoming the youngest victim of COVID-19, a 37-day-old baby in Greece who developed Acute Respiratory Distress Syndrome (ARDS) after contracting the deadly coronavirus died on March 8. Health Minister Vassilis Kikilias took to his official Twitter account to announce the sad news. According to the reports by The Greek City Times, the baby was being treated for approximately two weeks in the Intensive Care Unit of the Athenian children’s hospital “Aghia Sofia”.